论文部分内容阅读
目的:观察雷贝拉唑四联疗法治疗幽门螺杆菌(Hp)感染的临床疗效。方法:选择Hp阳性的消化性溃疡96例,随机分为观察组和对照组各48例。观察组给予雷贝拉唑+克拉霉素+阿莫西林+枸橼酸铋钾治疗,对照组给予奥美拉唑+克拉霉素+阿莫西林+枸橼酸铋钾治疗,疗程均为4周。比较两组Hp根除率及溃疡愈合率;随访6个月,比较两组Hp再感染及溃疡复发情况。结果:治疗4周后,观察组Hp根除率、溃疡愈合率分别为93.8%、97.9%,分别显著高于对照组的83.3%、89.6%(P<0.05);治疗后6个月随访,观察组Hp再感染率6.3%、溃疡复发率4.2%,分别显著低于对照组的20.8%、12.5%(P<0.05);两组均未发生明显不良反应。结论:雷贝拉唑四联疗法治疗Hp感染可提高Hp根除率、降低复发率,临床疗效较好。
Objective: To observe the clinical efficacy of rabeprazole quadruple therapy in the treatment of Helicobacter pylori (Hp) infection. Methods: 96 Hp-positive peptic ulcer patients were randomly divided into observation group and control group, 48 cases each. The observation group was treated with rabeprazole + clarithromycin + amoxicillin + bismuth potassium citrate, while the control group was given omeprazole + clarithromycin + amoxicillin + bismuth potassium citrate for 4 weeks week. Hp eradication rate and ulcer healing rate were compared between the two groups. After 6 months of follow-up, Hp re-infection and ulcer recurrence in both groups were compared. Results: After 4 weeks of treatment, the eradication rates of Hp and ulcer in the observation group were 93.8% and 97.9%, respectively, which were significantly higher than 83.3% and 89.6% (P <0.05) of the control group respectively. After 6 months of follow-up, The re-infection rate of Hp was 6.3% and the ulcer recurrence rate was 4.2%, which was significantly lower than that of the control group (20.8%, 12.5%, respectively) (P <0.05). No significant adverse reactions occurred in both groups. Conclusion: Rabeprazole quadruple therapy for Hp infection can improve the Hp eradication rate, reduce the recurrence rate, the clinical curative effect is better.